Is this you? Create Your Porfile
Avatar

Bruce Dzyngel

Sunovion

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Bruce Dzyngel is active.

Explore More

Publication

Featured researches published by Bruce Dzyngel.

Movement Disorders | 2016

Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease

Robert A. Hauser; C. Warren Olanow; Bruce Dzyngel; Thierry Bilbault; Holly A. Shill; Stuart Isaacson; Jordan Dubow; Albert Agro

OFF episodes negatively impact quality of life in patients with Parkinsons disease (PD). There remains a need for an acute, effective, noninvasive treatment.

Archive | 2004

Methods for treating sexual dysfunction

Kenneth R. Evans; Terrence Sills; Albert Agro; Bruce Dzyngel

Neurology | 2016

Efficacy of Sublingual Apomorphine (APL-130277) for the Treatment of OFF Episodes in Patients with Parkinson's Disease (P2.335)

Robert A. Hauser; Bruce Dzyngel; Thierry Bilbault; Holly A. Shill; Albert Argo

Parkinsonism & Related Disorders | 2016

Baseline disease severity not predictive of sublingual apomorphine (APL-130277) dose needed to convert a PD patient from the off to on state

Jordan Dubow; Bruce Dzyngel; Thierry Bilbault; Anthony Giovinazzo; Albert Agro

Neurology | 2016

The Effects of Sublingual Apomorphine (APL-130277) by Disease Severity on the Acute Management of OFF Episodes in Parkinson’s Disease (P2.336)

Holly A. Shill; Eric J. Pappert; Bruce Dzyngel; Thierry Bilbault; Albert Argo

Neurology | 2017

Disease severity does not predict effective ON-turning dose of apomorphine sublingual film (APL-130277) in patient with Parkinson’s disease (P1.023)

Hubert H. Fernandez; Stuart Isaacson; Alberto J. Espay; Rajesh Pahwa; Daniel Truong; Eric J. Pappert; Peter Gardzinski; Bruce Dzyngel; Albert Agro; Robert A. Hauser

Neurology | 2017

Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: results from the Phase 3 study dose-titration phase (P1.017)

Robert A. Hauser; Stuart Isaacson; Alberto J. Espay; Rajesh Pahwa; Daniel Truong; Eric J. Pappert; Peter Gardzinski; Bruce Dzyngel; Albert Agro; Hubert H. Fernandez

Parkinsonism & Related Disorders | 2016

The effects of sublingual apomorphine (APL-130277) by disease severity on the acute reversal of OFF episodes in Parkinson’s disease patients

Jordan Dubow; Bruce Dzyngel; Thierry Bilbault; Anthony Giovinazzo; Albert Agro

Parkinsonism & Related Disorders | 2016

Efficacy of sublingual apomorphine (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease

Albert Agro; Jordan Dubow; Bruce Dzyngel; Thierry Bilbault; Anthony Giovinazzo; Holly Shill; Robert A. Hauser

Parkinsonism & Related Disorders | 2016

Minimum MDS-UPDRS part III change needed to convert a Parkinson's disease patient from the OFF to full ON state with sublingual apomorphine (APL-130277)

Jordan Dubow; Bruce Dzyngel; Thierry Bilbault; Anthony Giovinazzo; Albert Agro

Explore More

Collaboration

Dive into the Bruce Dzyngel's collaboration.

Top Co-Authors
Avatar

Albert Agro

Sunovion

View shared research outputs
Top Co-Authors
Avatar

Jordan Dubow

Northwestern University

View shared research outputs
Top Co-Authors
Avatar

Robert A. Hauser

University of South Florida

View shared research outputs
Top Co-Authors
Avatar

Eric J. Pappert

Sunovion

View shared research outputs
Top Co-Authors
Avatar

Holly A. Shill

Barrow Neurological Institute

View shared research outputs
Top Co-Authors
Avatar

Stuart Isaacson

University of Salerno

View shared research outputs
Top Co-Authors
Avatar

Alberto J. Espay

University of Cincinnati

View shared research outputs
Top Co-Authors
Avatar

Hubert H. Fernandez

Cleveland Clinic

View shared research outputs
Top Co-Authors
Avatar

Peter Gardzinski

Sunovion

View shared research outputs
Top Co-Authors
Avatar

Rajesh Pahwa

University of Kansas

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge